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Condensation:  
Two-stage screening for preterm-preeclampsia offers a cost-saving alternative to 
one-stage screening. 
 
Short version of title: Preterm preeclampsia screening 
 
AJOG at a Glance 
 
A. First-trimester screening by a combination of maternal factors and three 
biomarkers identifies a high proportion of pregnancies that develop  
preterm-preeclampsia. The study explores the possibility of carrying out 
first-stage screening in the whole population by some of the biomarkers and 
proceeding to second-stage screening by the triple test only for a subgroup of 
the population selected on the basis of the risk derived from first-stage 
screening. 
 
B. Similar screen positive and detection rates can be achieved with a two-stage 
strategy of screening, if some of the biomarkers are included in the first-stage 
to select only 20-40% of the population in need of the complete triple test. 
 
C. Two-stage screening and biomarker testing for only part of the population will 
have financial benefits over conducting the test for the entire population. 
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ABSTRACT 
Background Screening for preeclampsia (PE) at 11-13 weeks’ gestation by a 
combination of maternal factors, mean arterial pressure (MAP), uterine artery 
pulsatility index (UtA-PI) and serum placental growth factor (PlGF) (triple test) can 
predict about 90% of PE, with delivery at <32 weeks (early-PE), and 75% of PE 
with delivery at <37 weeks (preterm-PE), at a screen positive rate (SPR) of 10%. 
In pregnancies identified as being at high-risk for PE by such screening, 
administration of aspirin (150 mg/day from 11-14 weeks’ gestation to 36 weeks) 
reduces the rate of early-PE by about 90% and preterm-PE by about 60%. 
Recording of maternal history and blood pressure are part of routine prenatal care 
but measurement of UtA-PI and PlGF require additional costs. 
Objective: To explore the possibility of carrying out first-stage screening in the 
whole population by maternal factors alone or a combination of maternal factors, 
MAP and UtA-PI or maternal factors, MAP and PlGF and proceeding to 
second-stage screening by the triple test only for a subgroup of the population 
selected on the basis of the risk derived from first-stage screening. 
Study design: The data for this study were derived from prospective 
non-intervention screening for PE at 11+0 – 13+6 weeks’ gestation in 61,174 
singleton pregnancies. Patient-specific risks of delivery with PE at <37 and <32 
weeks’ gestation were calculated using the competing risks model to combine the 
prior distribution of the gestational age at delivery with PE, obtained from maternal 
characteristics and medical history, with various combinations of multiple of the 
median (MoM) values of MAP, UtA-PI and PlGF. We estimated the detection rate 
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(DR) of preterm-PE and early-PE at overall SPR of 10%, 15% and 20%, from a 
policy in which first-stage screening of the whole population is carried out by some 
of the components of the triple test and second-stage screening by the full triple 
test on women selected on the basis of results from first-stage screening. 
Results: If the method of first-stage screening is maternal factors, then 
measurements of MAP, UtA-PI and PlGF can be reserved for only 70% of the 
population achieving similar DR and SPR as with screening the whole population 
with the triple test. In the case of first-stage screening by maternal factors, MAP 
and UtA-PI, then measurement of PlGF can be reserved for only 30-40% of the 
population and if first-stage screening is by maternal factors, MAP and PlGF, 
measurement of UtA-PI can be reserved for only 20-30% of the population. 
Empirical results were consistent with model-based performance. 
Conclusions: Two-stage screening and biomarker testing for only part of the 
population will have financial benefits over conducting the test for the entire 
population. 
 
Key words: First trimester screening, Preeclampsia, Aspirin, Bayes theorem, 
Contingent screening, Survival model, Uterine artery Doppler, Mean arterial 
pressure, Placental growth factor. 
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INTRODUCTION 
 
Identification of pregnancies at high-risk of developing preeclampsia (PE) at 11-13 
weeks’ gestation is beneficial because in such cases prophylactic use of aspirin 
(150 mg/day from 11-14 weeks’ gestation to 36 weeks) reduces the rate of 
early-PE, with delivery at <32 weeks, by about 90% and preterm-PE, with delivery 
at <37 weeks, by about 60%; but there is little evidence of a reduction in incidence 
of PE with delivery at term.1,2 Such screening and treatment is also associated 
with a reduction in length of stay in the neonatal intensive care unit by about 70%.3 
 
The established method of screening for PE is to identify risk factors from maternal 
demographic characteristics and medical history; in the presence of such factors 
the patient is classified as high-risk and in their absence as low-risk.4,5 The 
performance of this approach of screening is poor 6-8 and, though it is simple, it 
does not quantify individual patient specific risks. An alternative way of screening 
is to use logistic regression models fitted to maternal characteristics and medical 
history alone or in combination with biomarkers to predict early, late or all PE.9-13 
Such models are useful in quantifying the individual patient specific risk for PE, 
rather than just classifying women into high- and low-risk groups. However, they do 
not allow the flexibility of selecting different gestational age cut-offs for categorizing 
the severity of PE, they do not take into account the increasing effect of biomarkers 
with severity of the disease and they cannot be easily expanded to include 
additional biomarkers measured at different stages in pregnancy. We have 
proposed a competing risks approach which allows estimation of the individual 
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patient-specific risks of PE before any specified gestation and in the interval 
between any two gestational ages by a combination of maternal characteristics 
and medical history with  biomarkers obtained either individually or in 
combination at any stage in pregnancy.6,14-16 Screening by the competing risks 
approach at 11-13 weeks’ gestation by a combination of maternal characteristics 
and medical history with mean arterial pressure (MAP), uterine artery pulsatility 
index (UtA-PI) and serum placental growth factor (PlGF) can predict about 90% of 
early-PE and 75% of preterm-PE, at screen positive rate (SPR) of 10%.6,7,16,17 
Recording maternal characteristics and medical history, measurement of blood 
pressure and hospital attendance at 11-13 weeks’ gestation for an ultrasound 
scan are an integral part of routine antenatal care in many countries. In contrast, 
measurements of serum PlGF and UtA-PI are not part of routine care and would be 
associated with an additional cost. 
 
The objective of this study is to explore the possibility of carrying out first-stage 
screening in the whole population by maternal factors alone or a combination of 
maternal factors, MAP and UtA-PI or maternal factors, MAP and PlGF and 
proceeding to second-stage screening by a combination of maternal factors, MAP, 
UtA-PI and PlGF (triple test) only for a subgroup of the population selected on the 
basis of the risk derived from first-stage screening. 
 
MATERIALS AND METHODS 
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Study population 
 
The data for this study were derived from three previously reported prospective 
non-intervention screening studies at 11+0 - 13+6 weeks’ gestation in a combined 
total of 61,174 singleton pregnancies, including 1,770 (2.9%) that developed PE. 
The first study involved 35,948 pregnancies in two maternity hospitals in 
England,16 the second study, involved 8,775 pregnancies in 12 maternity 
hospitals in England, Spain, Belgium, Italy and Greece,18 and the third study, 
involved 16,451 pregnancies in seven maternity hospitals in England.7 Women 
with singleton pregnancies in the participating hospitals had a routine examination 
at 11+0 - 13+6 weeks’ gestation. This visit included first, recording of maternal 
characteristics and medical history,6 second, measurement of the left and right 
UtA-PI by transabdominal color Doppler ultrasound and calculation of the mean 
PI,19 third, measurement of MAP by validated automated devices and 
standardized protocol,20 and fourth, measurement of serum concentration of PlGF 
(DELFIA Xpress system, PerkinElmer Life and Analytical Sciences, Waltham, 
USA or BRAHMS KRYPTOR analyzer, Thermo Fisher Scientific, Hennigsdorf, 
Germany). Gestational age was determined from the fetal crown-rump length.21 
The women gave written informed consent to participate in the studies, which 
were approved by the relevant research ethics committee in each participating 
country. 
 
Patient characteristics including maternal age, racial origin (White, Black, South 
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Asian, East Asian and mixed), method of conception (spontaneous or assisted 
conception requiring the use of ovulation drugs or in vitro fertilization), cigarette 
smoking during pregnancy, medical history of chronic hypertension, diabetes 
mellitus, systemic lupus erythematosus (SLE) or anti-phospholipid syndrome 
(APS), family history of PE in the mother of the patient and obstetric history 
including parity (parous or nulliparous if no previous pregnancies at or after 24 
weeks), previous pregnancy with PE, gestational age at delivery and birth weight 
of the neonate in the last pregnancy and interval in years between birth of the last 
child and estimated date of conception of the current pregnancy. Maternal height 
and weight were measured. We have previously reported that increased risk for 
PE is provided by advancing maternal age, increasing weight, Black and South 
Asian racial origin, medical history of chronic hypertension, diabetes mellitus and 
SLE or APS, conception by in vitro fertilization, family history of PE and personal 
history of PE; in the latter group the risk is inversely related to the gestational age 
at delivery of the previous pregnancy.6 The risk for PE is decreased with 
increasing maternal height and in parous women with no previous PE; in the latter 
group, the maximum protective effect is when the interval between the current and 
previous pregnancy is 1-2 years, but the beneficial effect persists for more than 15 
years.6  
 
The inclusion criteria were singleton pregnancy undergoing first-trimester 
combined screening for aneuploidy and subsequently delivering a morphologically 
normal live birth or stillbirth at >24 weeks’ gestation. We excluded pregnancies 
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with aneuploidies and major fetal abnormalities and those ending in termination, 
miscarriage or fetal death at <24 weeks.  
 
Data on pregnancy outcome were collected from the hospital maternity records or 
the general medical practitioners of the women. The obstetric records of all women 
with pre-existing or pregnancy associated hypertension were examined to 
determine if the condition was PE, as defined by the International Society for the 
Study of Hypertension in Pregnancy.22 The outcome measures for this study were 
early-PE and preterm-PE. 
 
Statistical analysis 
The competing risks approach is based on a survival-time model for the 
gestational age at delivery with PE.6,16 In this approach it is assumed that if the 
pregnancy was to continue indefinitely all women would develop PE and whether 
they do so or not before a specified gestational age depends on competition 
between delivery before or after development of PE. The effects of variables from 
maternal factors and biomarkers is to modify the distribution of gestational age at 
delivery with PE so that in pregnancies at low risk for PE the gestational age 
distribution is shifted to the right with the implication that in most pregnancies 
delivery will actually occur before development of PE. In high-risk pregnancies the 
distribution is shifted to the left and the smaller the mean gestational age the 
higher is the risk for PE. Each woman has a personalized distribution of 
gestational age at delivery with PE and the risk of delivery with PE before a 
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specified gestational age, assuming no other cause delivery, is given by the area 
under the probability density curve. Bayes theorem is used to combine a prior 
distribution determined from maternal demographic and pregnancy characteristics 
with likelihoods from biomarkers to obtain the posterior distribution of time to 
delivery with PE. 
 
The performance of screening for PE was assessed via a two-stage strategy 
(Figure 1). On the basis of the results of first-stage screening the population was 
divided into a low-risk, screen negative group and a higher-risk group in need of 
further testing. After such testing the patients were again classified as 
screen-negative and screen-positive. The performance of three first-stage 
strategies was examined: screening of the whole population by maternal factors 
alone, maternal factors, MAP and UtA-PI and maternal factors, MAP and PlGF. 
The second stage test was the triple test. The proportion of women continuing to 
the second-stage and the overall SPR and DR for preterm-PE and early-PE were 
defined by various stage 1 and stage 2 risk cut-offs. 
 
The risk for development of PE is higher in women of Black or South Asian racial 
origin than in White women.6 Consequently in screening in a population of mixed 
racial origins, for a given risk cut-off, the DR and SPR would be higher in Black 
and South Asian than White women and the overall performance would be 
dependent on the proportion of the various racial groups within that population. 
The majority of our patients were White (44,684 / 61,174) and therefore decided to 
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develop a stratification model based on our population of White women and then 
observe the performance of screening in different racial groups. 
 
Predictive performance of two-stage risk stratification was assessed, and risk 
cut-offs were chosen, using previously published models and parameter 
estimates6,16,17. Empirical performance, for the sample of 61,174, using the same 
risk cut-off’s was then compared with model predictions results. Model based 
predictions were obtained by simulation from the fitted model as follows.  
Maternal characteristics, medical history and outcomes from the 44,684 records 
on White women were sampled with replacement to generate a simulated 
population of 1,000,000 individuals. MoM values for MAP, UtA-PI and PlGF were 
then simulated from the fitted multivariate Gaussian distribution for log transformed 
MoM values for this population cohort.16,17 Risks of PE with delivery <37 weeks 
were then calculated. This involved, for each individual, combining the maternal 
characteristic specific prior distribution with the likelihood from the MoM values 
using Bayes theorem to obtain the posterior distribution of time to delivery with PE. 
Risks were obtained from this by computing the probability of PE with delivery <37 
weeks. We chose to simulate a large population of 1,000,000 so that the 
imprecision in results induced by simulation was negligible. Risk cut-offs for the 
simulated data were selected so that the DR of preterm-PE was within 1% of that 
achieved by screening the whole population with the triple test. 
 
Empirical performance was assessed by applying the risk calculations described 
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above to the sample of 61,174 using the original MoM values and applying the risk 
cut-offs obtained from the simulation. Performance was assessed using estimates 
and confidence intervals for the proportions continuing to the second stage, for 
the overall screen positive rate and detection rate.   
 
The statistical software package R was used for data analyses.23   
 
RESULTS 
 
Characteristics of the study population 
 
The characteristics of the study population are summarized in Table 1. The 
incidence of all PE, preterm-PE and early-PE were 2.9%, 0.8% and 0.2%, 
respectively. In the PE group, compared to the no PE group, there was a higher 
median BMI and interpregnancy interval and frequency of self-identified Black 
women, chronic hypertension, diabetes mellitus, family history of PE, artificial 
conception, nulliparity and previous pregnancy with PE; the incidence of smoking 
was lower. 
 
Model-based performance of two-stage screening 
 
The model-based DR of preterm-PE and early-PE in women of White racial origin, 
at SPR of 10%, 15% and 20% are shown in Tables 2-4, respectively. In screening 
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the whole population by the triple test, at SPR of 10%, the DR of preterm-PE was 
67.0% and early-PE was 85.3%; the respective values at SPR of 15% were 75.6% 
and 90.1% and at SPR of 20% were 81.3% and 92.8%. 
 
In two-stage screening with maternal factors as the method of screening in the 
first-stage and reserving measurements of MAP, UtA-PI and PlGF for the 
second-stage to only 70% of the population, a similar DR was achieved as in 
screening the whole population by the triple test, irrespective of whether the screen 
positive rate was 10%, 15% or 20% (Tables 2-4; Figure 2). In the case of first-stage 
screening by maternal factors, MAP and UtA-PI, a similar DR was achieved as in 
screening the whole population with the triple test, by reserving measurement of 
PlGF in the second-stage to only about 30% of the population for an overall SPR of 
10% and 40% for SPR of 20%. In the case of first-stage screening by maternal 
factors, MAP and PlGF, a similar DR was achieved as in screening the whole 
population with the triple test, by reserving measurement of UtA-PI in the 
second-stage to only about 20% of the population for an overall SPR of 10% and 
30% for SPR of 20%.  
 
Empirical performance of two-stage screening 
 
On the basis of the model-based results, we selected the following risk cut-offs for 
preterm-PE to assess the empirical performance of screening at SPR of 10%. For 
the first-stage the risk cut-offs for selecting the group in need for second stage 
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screening was 1 in 600 when screening was by maternal factors, 1 in 300 in 
screening by a combination of maternal factors, MAP and UtA-PI and 1 in 200 in 
screening or maternal factors, MAP and PlGF. The risk cut-off for selecting the 
screen positive group after second stage screening was 1 in 100. 
 
Empirical performance of two-stage screening, at a fixed overall SPR of 10% for 
White women is shown in Table 5. At the selected risk cut-offs for first- and 
second-stage screening the proportion of the population requiring second-stage 
screening was about 70% when first-stage screening was by maternal factors, 
about 30% when first-stage screening was by a combination of maternal factors, 
MAP and UtA-PI and 20% for screening by maternal factors, MAP and PlGF. The 
observed DRs of preterm-PE were about 68% and for early-PE they were about 
85% and these rates were consistent with the model-based rates. 
 
At the same risk cut-offs for first- and second-stage screening as in White women, 
the overall SPR was about 35% for women of Black racial origin and about 16% 
for women of South Asian racial origin (Table 5). The proportion of Black and 
South Asian women requiring second-stage screening with each method of 
first-stage screening was considerably higher than in White women and the DR of 
preterm-PE was >90% and of early-PE it was >99%. 
 
On the basis of the model-based results, we selected the following risk cut-offs for 
preterm-PE to assess the empirical performance of screening at SPR of 15%. For 
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the first-stage the risk cut-offs for selecting the group in need for second stage 
screening was 1 in 600 when screening was by maternal factors, 1 in 350 in 
screening by a combination of maternal factors, MAP and UtA-PI and 1 in 250 in 
screening or maternal factors, MAP and PlGF. The risk cut-off for selecting the 
screen positive group after second stage screening was 1 in 150. Empirical 
performance is shown in Table 6. In White women, the proportion of the 
population requiring second-stage screening was about 70% when first-stage 
screening was by maternal factors, about 40% when first-stage screening was by 
a combination of maternal factors, MAP and UtA-PI and about 25% for screening 
by maternal factors, MAP and PlGF. The observed DRs of preterm-PE and 
early-PE were about 80% and 90%, respectively. 
 
On the basis of the model-based results, we selected the following risk cut-offs for 
preterm-PE to assess the empirical performance of screening at SPR of 20%. For 
the first-stage the risk cut-offs for selecting the group in need for second stage 
screening was 1 in 600 when screening was by maternal factors, 1 in 400 in 
screening by a combination of maternal factors, MAP and UtA-PI and 1 in 300 in 
screening or maternal factors, MAP and PlGF. The risk cut-off for selecting the 
screen positive group after second stage screening was 1 in 200. Empirical 
performance is shown in Table 7. In White women, the population requiring 
second-stage screening was about 70% when first-stage screening was by 
maternal factors, about 40% when first-stage screening was by a combination of 
maternal factors, MAP and UtA-PI and about 30% in screening by maternal 
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factors, MAP and PlGF. The observed DRs of preterm-PE and early-PE were 
about 80% and 90%, respectively. 
 
COMMENT 
Principal findings of this study 
The findings of the study demonstrated that in screening a population of White 
women by the triple test at 11-13 weeks’ gestation the DR of preterm-PE was 67% 
and that of early-PE was 85%, at SPR of 10%; the respective values at SPR of 
20% were 81% and 93%. A similar performance can be achieved by a two-stage 
strategy whereby only some of the components of the triple test are used to 
screen the whole population and the other components are reserved for only a 
portion of the total population. If the method of first-stage screening is maternal 
factors, then measurements of MAP, UtA-PI and PlGF can be reserved for only 
70% of the population. In the case of first-stage screening by maternal factors, 
MAP and UtA-PI, then measurement of PlGF can be reserved for only 30-40% of 
the population and if first-stage screening is by maternal factors, MAP and PlGF 
measurement of UtA-PI can be reserved for only 20-30% of the population.  
 
In the application of Bayes theorem the maternal factor derived prior risk has a 
strong influence on the posterior risk and therefore the performance of screening. 
The risk of development of PE in women of Black or South Asian racial origin is 
higher than in White women 6 and therefore in screening for PE with the same risk 
cut-offs as in White women the SPR and DR in these racial groups are 
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considerably higher. Inevitably the overall performance of screening in a racially 
mixed population will depend on the proportion of the various racial groups. This 
is analogous to screening for Down syndrome where the maternal age derived 
prior risk is combined with the measurement of first- and or second-trimester 
biomarkers to derive the posterior risk; at a fixed risk cut-off, both the SPR and DR 
increase with maternal age and therefore the overall performance of screening 
depends of the maternal age distribution of a given study population. 
 
Strengths and limitations 
The strengths of this large screening study are first, recording of data on maternal 
characteristics and medical history to identify known risk factors associated with 
PE, second, use of a specific methodology and appropriately trained doctors to 
measure UtA-PI and MAP and automated machines to provide reproducible 
measurements of PlGF, third, expression of the values of the biomarkers as MoMs 
after adjustment for factors that affect the measurements, fourth, use of Bayes 
theorem to combine the prior distribution of gestational age at delivery with PE 
from maternal factors with biomarkers to estimate patient-specific risks and the 
performance of screening for PE delivering at different stages of pregnancy and 
fifth, comparison of model-based and empirical results on performance of 
screening. 
 
The observed performance of two-stage screening apply to our study population 
and comparison between studies requires the appropriate adjustments for the 
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characteristics of the population under investigation. In the application of 
screening in different countries it is likely that adjustments would be necessary for 
the calculation of MoM values for the biomarkers and establishment of a system 
for quality assurance of the measurements. 
 
Previous studies on two-stage screening 
Previous studies have demonstrated that two-stage strategies provide a cost 
effective way of screening for Down syndrome; the performance of screening by a 
combination of first-trimester fetal nuchal translucency and first- and 
second-trimester serum biochemistry in all pregnancies, as in the integrated test, 
is similar to two-stage screening in which second-trimester testing is carried out in 
only about 25% of the population, identified by first-trimester screening as being at 
intermediate-risk.24,25 Another screening study for Downs proposed that 
after first-trimester combined screening the population would be stratified into 
high-, intermediate- and low-risk groups; the high-risk group would have invasive 
testing and the intermediate-risk group would have second-stage screening with 
assessment of the fetal nasal bone and Doppler flow in the ductus venosus and 
across the tricuspid valve to identify another high-risk group in need of invasive 
testing.26 More recently, a contingent strategy has been proposed for maternal 
blood cell-free DNA testing after the first trimester combined test.27 
 
In relation to screening for PE, in a previous study we proposed a two-stage 
strategy in which first-stage screening in all pregnancies is based on maternal 
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factors and MAP at 11-13 weeks’ gestation and on the basis of risks a group is 
selected for additional measurements of UtA-PI and PlGF.28 The study reported 
that the model-based DR of preterm-PE achieved by screening the whole 
population with the triple test could also be achieved by reserving measurements 
of UtA-PI and PlGF to only 50% of the population. 
 
Implications for clinical practice. 
The need for effective first-trimester screening for preterm-PE has become 
apparent by recent evidence that in women identified by such screening as being 
at high-risk for PE administration of aspirin starting before 16 weeks’ gestation 
reduces the rate of early-PE by about 90% and preterm-PE by 60%.1,2 The 
prediction of PE provided by the traditional approach to screening, based on a 
series of maternal characteristics and medical history which are treated as 
independent risk factors, is poor. A prospective study comparing NICE guidelines 
with our competing risk model incorporating the triple test demonstrated that at the 
same SPR the DR of preterm-PE with our approach was twice as high.7  
 
In screening by the triple test in a population of White women the DR of 
preterm-PE was 67%, at SPR of 10% and this increased to 76% at SPR of 15% 
and 81% at SPR of 20%. Randomized trials on the use of aspirin have reported 
that the drug is not associated with increased risk of adverse events and in the 
case of antepartum hemorrhage the risk may actually be reduced.29 In this respect, 
it may be acceptable that in screening for PE the SPR could be 15% or even 20% 
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so as to maximize the DR. The inevitable consequence of fixing a risk cut-off 
aiming to achieve a given SPR in a White population is that the rate would be 
considerably higher for women of Black or South Asian racial origin. An alternative 
strategy in screening is to fix the SPR to be the same for all racial groups and 
using different risk cut-offs for each group; in a multiracial society such strategy 
would not be easy to implement and in any case, it would be wrong because it 
would merely mask the increased risk for PE in certain racial groups.  
 
The findings of this study demonstrate that a similar SPR and DR can be achieved 
with a two-stage strategy of screening as with carrying out screening with all 
biomarkers in the whole population. Inevitably, biomarker screening for only part 
of the population will have financial benefits over conducting the test for the entire 
population. If the method of first-stage screening is maternal factors, then 
measurement of biomarkers can be reserved for only 70% of the population and if 
some of the biomarkers are included in first-stage screening then the need for the 
complete triple test can be reduced to 20-40% of the population. 
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Table 1. Characteristics of the screening population.  
 
 
PE = preeclampsia; IQR = interquartile range; SLE = systemic lupus erythematosus; APS = antiphospholipid syndrome. Please note that the all PE 
group includes all cases of PE <37 and PE <32 weeks and that the PE <37 weeks includes all cases of PE <32 weeks. *Comparisons between all 
PE and no PE groups were by chi-square or Fisher exact test for categorical variables and Mann Whitney-U test for continuous variables. 
 
Variable 
No PE  
(n=59,404) 
PE < 37 weeks 
(n=493) 
PE < 32 weeks 
(n=116) 
All PE 
(n=1,770) p-value * 
Maternal age in years, median (IQR 31.3 (27.1, 35.0) 32.1 (27.5, 36.0) 30.2 (25.9, 35.1) 31.45 (27.0, 35.3) 0.328 
Maternal weight in kg, median (IQR) 66.6 (59.0, 77.0) 74.0 (63.4, 86.7) 74.8 (65.0, 89.6) 73.2 (63.1, 86.9) <0.00001 
Maternal height in cm, median (IQR) 165 (160, 169) 163 (158, 168) 163 (159, 167) 164 (159, 168) <0.00001 
Body mass index, median (IQR) 24.5 (21.9, 28.4) 27.5 (23.9, 32.9) 28.2 (24.1, 33.8) 27.4 (23.6, 32.4) <0.00001 
Gestational age in weeks, median (IQR) 12.7 (12.3, 13.1) 12.7 (12.3, 13.1) 12.6 (12.2, 13.1) 12.7 (12.3, 13.1) 0.137 
Racial origin <0.00001 
  White, n (%) 43,663 (73.5) 256 (51.9) 48 (41.4) 1,021 (57.7)  
  Black, n (%) 9,539 (16.1) 183 (37.1) 56 (48.3) 569 (32.2) 
  South Asian, n (%) 3,332 (5.6) 38 (7.7) 9 (7.8) 114 (6.4) 
  East Asian, n (%) 1,383 (2.3) 4 (0.8) 0 (0.0) 24 (1.4) 
  Mixed, n (%) 1,487 (2.5) 12 (2.4) 3 (2.6) 42 (2.4) 
Medical history 
  Chronic hypertension 590 (1.0) 78 (15.8) 19 (16.4) 208 (11.8) <0.00001 
  Diabetes mellitus, n (%) 470 (0.8) 17 (3.4) 4 (3.5) 30 (1.7) <0.00001 
  SLE / APS, n (%) 104 (0.2) 5 (1.0) 0 (0.0) 7 (0.4) 0.062 
Smoker, n (%) 5,000 (8.4) 30 (6.1) 6 (5.2) 100 (5.7) 0.00004 
Family history of preeclampsia, n (%) 2,256 (3.8) 46 (9.3) 10 (8.6) 136 (7.7) <0.00001 
Method of conception 0.0015 
  Natural, n (%) 57,314 (96.5) 459 (93.1) 112 (96.6) 1,677 (94.7)  
  In vitro fertilization, n (%) 1,572 (2.6) 23 (4.7) 2 (1.7) 72 (4.1) 
  Ovulation drugs 517 (0.9) 11 (2.2) 2 (1.7) 21 (1.2) 
Parity <0.00001 
  Nulliparous, n (%) 28,014 (47.2) 271 (55.0) 61 (52.6) 1,061 (59.9)  
  Parous with no previous PE, n (%) 29,771 (50.1) 146 (29.6) 33 (28.4) 482 (27.2) 
  Parous with previous PE, n (%) 1,619 (2.7) 76 (15.4) 22 (19.0) 227 (12.8) 
Pregnancy interval in years, median (IQR) 2.9 (1.8, 4.8) 4.6 (2.6, 7.6) 4.4 (2.3, 7.4) 4 (2.3, 6.8) <0.00001 
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Table 2. Model-based performance of two-stage screening for preterm- and early-preeclampsia at overall screen positive rate of 10% 
in White women. First-stage screening is carried out in all pregnancies by maternal factors alone or a combination of maternal factors, 
MAP and UtA-PI or maternal factors, MAP and PlGF. Column 1 provides the proportion of the population proceeding to second stage 
screening which is carried out by the triple test. The grey boxes highlight the similarity in detection rate of preterm-preeclampsia 
between the triple test in all pregnancies and two-stage screening in which the triple test is reserved for only some women. 
 
Proportion 
continuing to 
stage 2 (%) 
First stage screening by history First stage screening by history + MAP + UtA-PI First stage screening by history + MAP + PlGF 
Risk cut-offs Detection rate of PE (%) Risk cut-offs Detection rate of PE (%) Risk cut-offs Detection rate of PE (%) 
Stage 1 Stage 2 <37 w <32 w Stage 1 Stage 2 <37 w <32 w Stage 1 Stage 2 <37 w <32 w 
100 - 94 67.0 85.3 - 94 67.0 85.3 - 94 67.0 85.3 
95 1876 94 67.0 85.3 6328 94 67.0 85.3 8477 94 67.0 85.3 
90 1392 95 67.0 85.3 3731 94 67.0 85.3 4823 94 67.0 85.3 
85 1089 95 67.0 85.3 2587 94 67.0 85.3 3285 94 67.0 85.3 
80 884 95 67.0 85.3 1930 94 67.0 85.3 2408 94 67.0 85.3 
75 703 96 66.7 84.4 1499 94 67.0 85.3 1846 94 67.0 85.3 
70 560 96 66.6 84.6 1195 94 67.0 85.3 1456 94 67.0 85.3 
65 437 98 66.1 83.0 969 94 67.0 85.3 1170 94 67.0 85.3 
60 349 99 65.6 81.6 796 94 67.0 85.3 951 94 67.0 85.3 
55 298 102 64.8 79.8 659 95 67.0 85.3 779 94 67.0 85.3 
50 265 106 63.6 77.1 549 95 66.9 85.2 641 94 67.0 85.3 
45 240 111 62.5 76.6 459 95 67.0 85.2 528 94 67.0 85.3 
40 219 118 61.4 75 382 95 66.9 85.2 434 94 67.0 85.3 
35 200 127 60.6 73.2 317 96 66.7 84.9 355 95 67.0 85.3 
30 182 140 57.2 64.7 260 98 66.7 84.7 288 95 67.0 85.2 
25 163 162 54.9 61.4 211 102 66.4 84.6 229 96 67.1 85.4 
20 145 202 50.0 57.5 167 110 65.8 83.4 178 99 67.0 84.8 
15 123 305 45.4 52 127 134 64.1 80.7 132 109 66.2 83.9 
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Table 3. Model-based performance of two-stage screening for preterm- and early-preeclampsia at overall screen positive rate of 15% 
in White women. First-stage screening is carried out in all pregnancies by maternal factors alone or a combination of maternal factors, 
MAP and UtA-PI or maternal factors, MAP and PlGF. Column 1 provides the proportion of the population proceeding to second stage 
screening which is carried out by the triple test. The grey boxes highlight the similarity in detection rate of preterm-preeclampsia 
between the triple test in all pregnancies and two-stage screening in which the triple test is reserved for only some women. 
 
Proportion 
continuing to 
stage 2 (%) 
First stage screening by history First stage screening by history+MAP+UtPI First stage screening by history+MAP+PlGF 
Risk cut-offs Detection rate Risk cut-offs Detection rate Risk cut-offs Detection rate 
Stage 1 Stage 2 <37 w <32 w Stage 1 Stage 2 <37 w <32 w Stage 1 Stage 2 <37 w <32 w 
100 - 141 75.6 90.1 - 141 75.6 90.1 - 141 75.6 90.1 
95 1876 141 75.5 90.1 6328 141 75.6 90.1 8477 141 75.6 90.1 
90 1392 142 75.5 90.1 3731 141 75.6 90.1 4823 141 75.6 90.1 
85 1089 142 75.4 90.0 2587 141 75.6 90.1 3285 141 75.6 90.1 
80 884 143 75.4 90.1 1930 141 75.6 90.1 2408 141 75.6 90.1 
75 703 144 74.9 88.8 1499 141 75.6 90.1 1846 141 75.6 90.1 
70 560 146 74.7 88.8 1195 141 75.6 90.1 1456 141 75.6 90.1 
65 437 149 74.3 87.2 969 141 75.6 90.1 1170 141 75.6 90.1 
60 349 153 73.3 85.4 796 141 75.6 90.1 951 141 75.6 90.1 
55 298 159 72.1 82.8 659 142 75.5 90.0 779 141 75.6 90.1 
50 265 168 70.7 80.3 549 142 75.4 89.9 641 141 75.6 90.1 
45 240 179 68.9 79.1 459 144 75.3 90.0 528 141 75.5 89.9 
40 219 195 67.6 77.6 382 146 75.2 89.9 434 142 75.4 89.9 
35 200 218 66.1 75.9 317 150 75.0 89.4 355 143 75.4 90.0 
30 182 256 61.6 66.3 260 157 74.5 88.7 288 145 75.3 89.8 
25 163 323 58.7 62.7 211 172 73.7 88.3 229 151 75.3 89.9 
20 145 496 52.5 58.1 167 212 72.0 86.6 178 171 74.5 88.5 
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Table 4. Model-based performance of two-stage screening for preterm- and early-preeclampsia at overall screen positive rate of 20% 
in White women. First-stage screening is carried out in all pregnancies by maternal factors alone or a combination of maternal factors, 
MAP and UtA-PI or maternal factors, MAP and PlGF. Column 1 provides the proportion of the population proceeding to second stage 
screening which is carried out by the triple test. The grey boxes highlight the similarity in detection rate of preterm-preeclampsia 
between the triple test in all pregnancies and two-stage screening in which the triple test is reserved for only some women. 
 
 
 
Proportion 
continuing to 
stage 2 (%) 
First stage screening by history First stage screening by history + MAP + UtA-PI First stage screening by history + MAP + PlGF 
Risk cut-offs Detection rate of PE (%) Risk cut-offs Detection rate of PE (%) Risk cut-offs Detection rate of PE (%) 
Stage 1 Stage 2 <37 w <32 w Stage 1 Stage 2 <37 w <32 w Stage 1 Stage 2 <37 w <32 w 
100 - 194 81.3 92.8 - 194 81.3 92.8 - 194 81.3 92.8 
95 1876 194 81.3 92.9 6328 194 81.3 92.8 8477 194 81.3 92.8 
90 1392 195 81.3 92.9 3731 194 81.3 92.8 4823 194 81.3 92.8 
85 1089 196 81.2 92.8 2587 194 81.3 92.8 3285 194 81.3 92.8 
80 884 197 81.2 92.9 1930 194 81.3 92.8 2408 194 81.3 92.8 
75 703 200 80.6 91.4 1499 194 81.3 92.8 1846 194 81.3 92.8 
70 560 203 80.3 91.4 1195 194 81.3 92.9 1456 194 81.3 92.8 
65 437 209 79.5 89.5 969 194 81.3 92.9 1170 194 81.3 92.8 
60 349 217 78.3 87.7 796 195 81.4 92.9 951 194 81.3 92.8 
55 298 229 76.9 85.0 659 196 81.4 92.8 779 194 81.3 92.8 
50 265 246 75.2 82.1 549 198 81.2 92.7 641 194 81.3 92.9 
45 240 269 72.8 80.8 459 201 81 92.6 528 195 81.3 92.8 
40 219 303 71.1 78.5 382 208 80.7 92.6 434 197 81.3 92.8 
35 200 356 69.1 76.5 317 220 79.9 91.7 355 201 81.1 92.6 
30 182 454 64.4 66.9 260 243 79.0 90.7 288 211 80.9 92.4 
25 163 700 60.6 63.0 211 302 77.7 89.8 229 241 80.4 91.7 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
30 
 
Table 5. Empirical and model-based performance of two-stage screening at 11-13 weeks’ gestation for preeclampsia (PE) 
with delivery at <37 and <32 weeks’ gestation, at a fixed overall screen positive rate of 10% for White women, in the 
population subdivided according to racial origin. Second-stage screening is by a combination of maternal factors, MAP, 
UtA-PI and PlGF. The risk cut-off for preterm PE for selecting the group in need for second-stage screening is 1 in 600 
when first-stage screening is by maternal factors and 1 in 300 when screening is by a combination of maternal factors, 
MAP and UtA-PI and 1 in 200 in screening by maternal factors, MAP and PlGF. The risk cut-off for selecting the screen 
positive group after second-stage screening is 1 in 100. The numbers in bold are the model-based values for White 
women. 
 
 
 
 
 
Method of 1st stage 
screening 
Racial 
group 
Need for 2nd stage 
screening (%) 
Screen positive 
rate, % (95% CI) 
Detection rate of preeclampsia, % (95% CI) 
<37 weeks <32 weeks 
Maternal factors 
White 
71.4 10.4 67.6 85.0 
71.4 10.2 (9.9, 10.5) 67.6 (61.5, 73.3) 83.3 (69.8, 92.5) 
Black 98.8 34.0 (33.0, 34.9) 92.3 (87.5, 95.8) 100 (93.6, 100) 
South Asian 88 16.5 (15.3, 17.8) 97.4 (86.2, 99.9) 100 (66.4, 100) 
Maternal factors 
+ MAP + UtA-PI 
White 
33.6 10.3 67.4 85.2 
34.7 10.1 (9.8, 10.4) 68.8 (62.7, 74.4) 85.4 (72.2, 93.9) 
Black 68.8 33.5 (32.6, 34.5) 92.3 (87.5, 95.8) 100 (93.6, 100) 
South Asian 47.6 16.2 (15.0, 17.5) 97.4 (86.2, 99.9) 100 (66.4, 100) 
Maternal factors 
+ MAP + PlGF 
White 
22.2 10.3 67.5 85.5 
21.6 10.1 (9.8, 10.4) 67.2 (61.1, 72.9) 85.4 (72.2, 93.9) 
Black 54.4 33.7 (32.8, 34.7) 91.8 (86.8, 95.3) 100 (93.6, 100) 
South Asian 30.3 16.3 (15.1, 17.6) 97.4 (86.2, 99.9) 100 (66.4, 100) 
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Table 6. Empirical and model-based performance of two-stage screening at 11-13 weeks’ gestation for preeclampsia (PE) 
with delivery at <37 and <32 weeks’ gestation, at a fixed overall screen positive rate of 15% for White women, in the 
population subdivided according to racial origin. Second-stage screening is by a combination of maternal factors, MAP, 
UtA-PI and PlGF. The risk cut-off for preterm PE for selecting the group in need for second-stage screening is 1 in 600 
when first-stage screening is by maternal factors and 1 in 350 when screening is by a combination of maternal factors, 
MAP and UtA-PI and 1 in 250 in screening by maternal factors, MAP and PlGF. The risk cut-off for selecting the screen 
positive group after second-stage screening is 1 in 150. The numbers in bold are the model-based values for White 
women. 
Method of 1st stage 
screening 
Racial 
group 
Need for 2nd stage 
screening (%) 
Screen positive 
rate, % (95% CI) 
Detection rate of preeclampsia, % (95% CI) 
<37 weeks <32 weeks 
Maternal factors 
White 
71.4 15.5 75.5 89.3 
71.4 15.2 (14.8, 15.5) 78.1 (72.6, 83) 89.6 (77.3, 96.5) 
Black 98.8 43.3 (42.3, 44.3) 95.6 (91.6, 98.1) 100 (93.6, 100) 
South Asian 88.0 22.6 (21.2, 24.1) 97.4 (86.2, 99.9) 100 (66.4, 100) 
Maternal factors 
+ MAP + UtA-PI 
White 
37.7 15.2 75.5 89.9 
39.0 15.0 (14.7, 15.4) 80.1 (74.7, 84.8) 93.8 (82.8, 98.7) 
Black 72.6 42.7 (41.7, 43.7) 95.6 (91.6, 98.1) 100 (93.6, 100) 
South Asian 52.5 22.3 (20.9, 23.7) 97.4 (86.2, 99.9) 100 (66.4, 100) 
Maternal factors 
+ MAP + PlGF 
White 
26.9 15.1 75.6 90.1 
26.2 14.9 (14.6, 15.2) 78.1 (72.6, 83.0) 87.5 (74.8, 95.3) 
Black 59.9 42.8 (41.8, 43.7) 94.5 (90.2, 97.3) 100 (93.6, 100) 
South Asian 35.9 22.4 (21.0, 23.8) 97.4 (86.2, 99.9) 100 (66.4, 100) 
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Table 7. Empirical and model-based performance of two-stage screening at 11-13 weeks’ gestation for preeclampsia (PE) 
with delivery at <37 and <32 weeks’ gestation, at a fixed overall screen positive rate of 20% for White women, in the 
population subdivided according to racial origin. Second-stage screening is by a combination of maternal factors, MAP, 
UtA-PI and PlGF. The risk cut-off for preterm PE for selecting the group in need for second-stage screening is 1 in 600 
when first-stage screening is by maternal factors, 1 in 400 when screening is by a combination of maternal factors, MAP 
and UtA-PI and 1 in 300 in screening by maternal factors, MAP and PlGF. The risk cut-off for selecting the screen positive 
group after second-stage screening is 1 in 200. The numbers in bold are the model-based values for White women. 
 
 
 
Method of 1st stage 
screening 
Racial 
group 
Need for 2nd stage 
screening (%) 
Screen positive 
rate, % (95% CI) 
Detection rate of preeclampsia, % (95% CI) 
<37 weeks <32 weeks 
Maternal factors 
White 
71.4 19.8 80.3 91.3 
71.4 19.5 (19.2, 19.9) 80.5 (75.1, 85.1) 89.6 (77.3, 96.5) 
Black 98.8 50.3 (49.4, 51.3) 98.3 (95.3, 99.7) 100 (93.6, 100) 
South Asian 88.0 28.6 (27.1, 30.2) 97.4 (86.2, 99.9) 100 (66.4, 100) 
Maternal factors 
+ MAP + UtA-PI 
White 
41.3 19.6 80.5 92.2 
42.4 19.4 (19.0, 19.8) 82.8 (77.6, 87.2) 93.8 (82.8, 98.7) 
Black 75.8 49.5 (48.5, 50.5) 97.8 (94.5, 99.4) 100 (93.6, 100) 
South Asian 56.3 28.3 (26.8, 29.8) 97.4 (86.2, 99.9) 100 (66.4, 100) 
Maternal factors 
+ MAP + PlGF 
White 
31.0 19.4 80.5 92.1 
30.3 19.2 (18.8, 19.5) 81.2 (75.9, 85.8) 89.6 (77.3, 96.5) 
Black 64.4 49.5 (48.6, 50.5) 97.3 (93.7, 99.1) 100 (93.6, 100) 
South Asian 40.4 27.8 (26.3, 29.3) 97.4 (86.2, 99.9) 100 (66.4, 100) 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
33 
 
FIGURE LEGENDS 
Figure 1. Two stage screening for preterm preeclampsia.  
Figure 2. Relationship between model-based detection rate of preeclampsia with 
delivery at <37 weeks’ gestation (black curve), <34 weeks (blue curve) and <32 
weeks (red curve) and percentage of the population requiring second-stage 
screening at a fixed overall screen positive rate of 20% in women of White racial 
origin. 
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